Immunate (Human Coagulation Factor Viii, Human Von Willebrand Factor)

The factor VIII component participates in the intrinsic pathway of the coagulation cascade, converting factor X to Xa and ultimately generating thrombin. The von Willebrand factor stabilizes factor VIII in circulation and promotes platelet adhesion to damaged vascular surfaces, together restoring normal hemostasis.

The dose of Immunate is individualized and determined by the prescribing clinician based on the patient’s weight, severity of deficiency, type of bleeding episode, and surgical requirements. The prescriber calculates the required units to achieve target factor levels and adjusts as needed.

Safety data for Immunate in pregnancy and lactation are limited. The decision to use the product should be made by a qualified healthcare professional after weighing the potential benefits for the mother against any possible risks to the fetus or infant.

To request Immunate, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and import documentation.

Immunate is a plasma‑derived concentrate containing both factor VIII and von Willebrand factor, offering dual replacement in a single product. Compared with recombinant factor VIII products, Immunate may provide additional von Willebrand activity, which can be advantageous for patients with combined deficiencies, though the choice depends on individual clinical needs and product availability.

Immunate should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If temperature excursions occur, consult the product’s stability guidelines before use.

Immunate is supplied as a sterile solution for injection and is administered intravenously. The infusion rate and volume are determined by the prescriber, and patients are typically monitored during and after the infusion for any adverse reactions.

Serious risks include the development of inhibitory antibodies against factor VIII or von Willebrand factor, severe allergic or anaphylactic reactions, and thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. Prompt recognition and management of these events are essential.

Immunate is contraindicated in individuals with known hypersensitivity to any component of the product, including plasma‑derived proteins. Patients with a history of severe allergic reactions to factor concentrates should avoid its use, and clinicians should assess each case individually.